- Active not recruitingPHASE3
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study compares two drug combinations for people with multiple myeloma that has come back or not responded well to previous treatments. It aims to see if a new combination with belantamab mafodotin is better or safer than a standard treatment.
For: Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruiting
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
This study looks at how a medicine called isatuximab works for people in the UK with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It checks how well it works and if it's safe in real-world settings.
For: Plasma Cell MyelomaUnited States · Argentina · Austria - RecruitingPHASE2
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
This study is testing a new combination of medicines – inobrodib, pomalidomide, and dexamethasone – for people in the UK with multiple myeloma that has come back and is no longer responding to usual treatments. The aim is to see how well these medicines work together and what side effects they might cause.
For: Multiple Myeloma Refractory · Multiple Myeloma in RelapseUnited States · United Kingdom - Active not recruitingPHASE2
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at adding a drug called cyclophosphamide to a combination of pomalidomide and dexamethasone for people with multiple myeloma that has come back or isn't responding to treatment. We want to see if adding it helps patients live longer without their disease getting worse.
For: Multiple MyelomaUnited Kingdom - Active not recruitingPHASE1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is looking at a new medicine called talquetamab, combined with other treatments, for people with multiple myeloma. The main goal is to find safe doses and understand how well these combinations work together.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
This study is testing a new medicine, sonrotoclax, for people in the UK with multiple myeloma that has come back or isn't responding to treatment. Researchers want to see how safe and effective it is, both on its own and with other common myeloma drugs.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
For: Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
This study looks at a new drug, surzetoclax, for multiple myeloma that has come back or not responded to other treatments. It checks how safe it is and how well it works, sometimes alone and sometimes with other medicines. We're looking for adults with this type of myeloma.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
For: Relapsed Refractory Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, Cevostamab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to check its safety, how it moves in the body, and if it helps when given alone or with other medicines.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new treatment, teclistamab, with existing therapies for multiple myeloma that has come back or not responded to previous treatments. It aims to see how well teclistamab works and if it's safe for people with this condition.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
This study looks at new drug combinations for multiple myeloma that has come back or isn’t responding to treatment. It compares a drug called talquetamab, alone or with another drug called daratumumab, against a standard treatment of daratumumab, pomalidomide, and dexamethasone.
For: Multiple MyelomaUnited States · Belgium · Brazil - RecruitingPHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
This study is testing a new medicine called elranatamab for people with a type of blood cancer called multiple myeloma. It's for those whose cancer has returned after other treatments. We want to see if elranatamab works better than standard medicines.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
This study compares two treatments, Venetoclax plus Dexamethasone, and Pomalidomide plus Dexamethasone, for people with a specific type of multiple myeloma (t(11;14)-positive) that has come back or not responded to previous treatments. It aims to see which treatment works best at preventing the disease from getting worse.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
For: Relapsed or Refractory Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study looks at a new drug, linvoseltamab, for multiple myeloma that has come back or isn't responding to treatment. It compares linvoseltamab alone or with another drug, carfilzomib, against standard treatments to see if it's safer and works better.
For: Relapsed and/or Refractory Multiple Myeloma (RRMM)United States · Australia · South Korea - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
This study compares a new treatment called BMS-986393 with standard medicines for adults with multiple myeloma that has come back or not responded to previous treatment, including lenalidomide. We want to see if the new medicine works better and is safe.
For: Relapsed or Refractory Multiple Myeloma (RRMM)United States · Argentina · Australia - RecruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
This study compares a new cell therapy (Cilta-cel) with standard treatments for multiple myeloma, a type of blood cancer. It's for people whose cancer has returned or isn't responding to their current medicine, especially lenalidomide, to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
For: Relapsed Refractory Multiple Myeloma (RRMM)United States · Australia · Belgium - Active not recruitingPHASE1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, etentamig, along with existing cancer treatments for adults with multiple myeloma that has come back or isn't responding to treatment. We want to see how safe it is and if it helps reduce the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Germany - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
For: Multiple MyelomaUnited States · Argentina · Belgium - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
For: Multiple MyelomaUnited States · Belgium · Canada - Active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This study is looking at a new way to give a medicine called isatuximab for a type of blood cancer called multiple myeloma. It compares giving the medicine as a shot under the skin versus through a drip into a vein, always with other standard treatments.
For: Plasma Cell Myeloma RecurrentUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
This study looks at new ways to treat a blood cancer called multiple myeloma. It combines an existing medicine, Daratumumab, with newer ones (Talquetamab or Teclistamab), sometimes with Pomalidomide. The main goal is to find safe doses and see how well these combinations work.
For: Multiple MyelomaUnited States · Canada · Germany - RecruitingPHASE1, PHASE2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
This study looks at new drug combinations with isatuximab and other treatments for a type of blood cancer called multiple myeloma. It aims to find better ways to treat patients whose cancer has come back or hasn't responded to previous treatments.
For: Plasma Cell Myeloma RefractoryUnited States · Australia · France - RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study looks at a new way to give belantamab mafodotin, along with other common medicines, for multiple myeloma that has come back or isn't responding well. We want to see if giving it less often can still work well and cause fewer eye side effects.
For: Multiple MyelomaUnited States · France · Germany - RecruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
For: Multiple MyelomaUnited States · Belgium · Brazil - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
For: Multiple MyelomaUnited States · Argentina · Australia